Nemera’s preservative-free multi-dose eye dropper Novelia approved

Aché partners with Nemera to bring Novelia to Brazilian market

288
Clilon: Nemera's preservative-free formulation
Aché's Laxime for patients with dry eye syndrome

Nemera is excited to announce that its multi-dose eye dropper Novelia has been approved by ANVISA for the preservative-free formulations Clilon [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.

Established for over 54 years, São Paulo-based Aché is one of Brazil’s largest domestic pharmaceutical companies. [2] The Ketorolac products will first be commercialized in a preservative-free multi-dose format in the Brazilian market. These products will be available under prescription only.

Aché is also launching, in parallel, Laxime [3] (Sodium Hyaluronate 0,15%) over the counter (OTC) solution for patients with dry eye syndrome using Novelia.

Aché's Laxime for patients with dry eye syndrome
Aché’s Laxime for patients with dry eye syndrome

The Brazilian market presented a 4% growth ($ PMB IQVIA) in 2020 [4], with dry eye disease experiencing double-digit growth, making it the no.1 category in Brazil within the Ophthalmology market. [5]

Aché partnering with Nemera to improve people’s lives

“The entry of Aché in this segment represents an important reinforcement to the company’s large portfolio. With the mission of enhancing people’s health and longevity, we understand that we also needed to work with ophthalmology to bring the quality and technology of Aché’s products to this medical class. Our goal is not only to offer other options for the medical indication, but also to bring innovation to the Brazilian market in the coming years, and this partnership with Nemera will add great value to our products,” Marcelo Neri, Executive Director of Aché.

“It’s fantastic to see Aché bringing these products to the Brazilian market for the first time and expanding Novelia’s global reach to improve patients’ lives in Latin America. With a growing number of patients suffering from chronic eye conditions, effective drug delivery and patient adherence are increasingly important. Combining the huge advantages of preservative-free formulations to avoid patient irritations with the ease of a multi-dose container system is a win-win, and we are very proud to be partnering with Aché in this launch,” Denise Johnston, Vice President Global Sales at Nemera.

Novelia is a multi-dose closing tip dispensing system that avoids the need for preservatives in the drug and prevents bacterial contamination throughout treatment. A non-return valve system ensures that no contaminated liquid can be re-introduced into the container after the drop has been dispensed. In addition, the patented PureFlow technology (a separate venting system with a silicone membrane) guarantees the intake of air that is free of contamination into the dispenser after drop delivery.

With well over 200 market references worldwide, Novelia is the patient’s preferred choice when it comes to preservative-free multi-dose eyedroppers [6] thanks to its patented blue tip to help in targeting the eye, precise and consistent drop size, and patient-friendly ergonomics, including initiative screw-on cap and optimum squeeze force.

  1. Clilon. Prescribing information. Aché Laboratórios Farmacêuticos S.A.
  2. Annual Report. Aché Laboratórios Farmacêuticos S.A.
  3. Laxime. Prescribing information. Aché Laboratórios Farmacêuticos S.A.
  4. IQVIA. Dec/2020.
  5. Kairos Web Brasil. Available at: https://br.kairosweb.com/. March/2021.
  6. Internal Report. Novelia. User study performed for Nemera by an external party to understand the Novelia market opportunities versus competitors”. 76% of patients preferred Novelia over other marketed devices. GfK report, Paris, France, (2015).Note: this article first appeared on www.healthtekpak.com

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now

LEAVE A REPLY

Please enter your comment!
Please enter your name here